Plain-English translation of NCT06747585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called , which is an antibody-drug combination designed to target a specific protein found on certain squamous cell cancers. Researchers want to find the safest and most effective dose of this medication, and then see how well it works against advanced cancers of the lung, head and neck, cervix, or esophagus that have stopped responding to standard treatments. The trial has two main parts: first, doctors will carefully increase the dose to find the right amount, and then they will test that dose in more patients to measure how well it works.
Squamous cell cancers that have spread or stopped responding to standard treatments are very difficult to treat, and many patients have limited options. This medication was designed to attack these cancers in a new way, by targeting a protein called Claudin-1 that appears on these specific cancer types, which could offer hope to patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication through an intravenous infusion (IV) on a regular schedule determined by the trial doctors. The trial has multiple phases: in the first phase, the dose will be gradually increased in small groups of patients to find the safest dose; in the second phase, more patients will receive the established safe dose to see how well it works. You will have regular visits for blood tests, scans, and check-ups to monitor how you are responding and to watch for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States